According to Techmeme, Sam Altman is co-founding Merge Labs, a brain-computer interface startup that will use ultrasound and gene therapy to interact with neurons. The company has reportedly been raising $250 million at an $850 million valuation, with most capital coming directly from OpenAI. This development signals a major new competitor entering the brain-computer interface space with a fundamentally different approach than existing players.
Table of Contents
Understanding the Technical Approach
Merge Labs’ proposed method represents a radical departure from current brain-computer interface approaches. While companies like Neuralink rely on physical electrode arrays implanted directly into brain tissue, Merge aims to use ultrasound waves to interact with genetically modified neurons. This non-invasive strategy could potentially avoid the significant surgical risks and immune response challenges that have plagued implanted devices. The gene therapy component suggests they’re exploring ways to make neurons more responsive to external stimuli, potentially creating a two-way communication system without physical penetration of the brain.
Critical Analysis of the Approach
The technical challenges facing Merge Labs are substantial. Ultrasound has notoriously poor resolution for neural applications compared to direct electrode contact, and the blood-brain barrier presents significant obstacles for both ultrasound penetration and gene therapy delivery. The regulatory pathway for combining gene therapy with neural interfaces is virtually uncharted territory, likely requiring years of safety studies before human trials. Additionally, the ethical considerations of genetically modifying human neurons for interface purposes raise profound questions that neither the company nor regulators have adequately addressed publicly.
Industry Impact and Competitive Landscape
Merge Labs represents the most significant challenge yet to Neuralink‘s dominance in the high-profile BCI space. While numerous academic and smaller commercial efforts exist, none have combined Altman’s profile with OpenAI’s financial backing. The substantial investment from OpenAI suggests this isn’t a side project but a strategic priority that could leverage OpenAI’s AI expertise for neural decoding applications. This creates a fascinating competitive dynamic where Sam Altman‘s companies could potentially develop integrated AI-brain systems, though the practical timeline for such integration remains distant.
Realistic Outlook and Challenges
The road to commercial viability for Merge Labs is likely measured in decades rather than years. Beyond the scientific hurdles, the company must navigate unprecedented regulatory scrutiny for what amounts to two high-risk technologies combined. Public acceptance of genetically modified neurons, even for therapeutic purposes, represents another major hurdle. While the non-invasive approach offers theoretical safety advantages, the fundamental trade-off between invasiveness and signal quality remains unresolved in neuroscience. Success will require breakthroughs across multiple scientific disciplines simultaneously, making this one of the most ambitious—and risky—ventures in the emerging neurotechnology landscape.
